Copyright ©The Author(s) 2019.
World J Clin Cases. Jun 6, 2019; 7(11): 1253-1261
Published online Jun 6, 2019. doi: 10.12998/wjcc.v7.i11.1253
Table 3 Studies about antibiotics and immunotherapy
Research subjectsTumor typePatients No.Research conclusionRef.
1PatientsNSCLC/RCC/urothelial carcinoma249ATB use presents a predictor of resistance to ICIRouty et al[44], 2018
2PatientsNSCLC74ATB use does not affect the efficacy of nivolumabKaderbhai et al[43], 2017
3PatientsRCC/NSCLC360ATB use reduces clinical benefit from ICIDerosa et al[45], 2018
4MiceLymphoma/colon cancer/melanomaATB treated mice respond poorly to CpG-oligonucleotideLida et al[42], 2013
5MiceATB mice are resistant to cyclophosphamideViaud et al[41], 2013